Patients with chronic obstructive pulmonary disease (COPD) that is in a state of disease stability (DS) have fewer exacerbations and lower mortality, according to study findings published in Chest.

A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the completion of its Phase IIa clinical study for 9MW1911, a self-developed ...

The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key ...

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

According to a recent study, patients with an exacerbation of chronic obstructive pulmonary disease (COPD) have greater risks of both subsequent exacerbations and mortality. The odds of subsequent ...

—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...

Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA? Treatment with once-daily single-inhaler fluticasone ...

Please provide your email address to receive an email when new articles are posted on . Minimum pitch in the morning was significantly higher at exacerbation onset and peak vs. baseline. In the ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.